Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Hashimoto, M. Articles by Mori, E. Search for Related Content PubMed Citation Articles by Hashimoto, M. Articles by Mori, E. Alzheimer's Disease Other Somatic Therapy Genetics Neurodegeneration

Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer’s Disease?

OBJECTIVE: The only approved pharmacological approach for the symptomatic treatment of Alzheimer’s disease in Japan is the use of a cholinesterase inhibitor, donepezil hydrochloride. Recent in vivo and in vitro studies raise the possibility that cholinesterase inhibitors can slow the progression of Alzheimer’s disease. The purpose of the present study was to determine whether donepezil has a neuroprotective effect in Alzheimer’s disease by using the rate of hippocampal atrophy as a surrogate marker of disease progression. METHOD: In a prospective cohort study, 54 patients with Alzheimer’s disease who received donepezil treatment and 93 control patients with Alzheimer’s disease who never received anti-Alzheimer drugs underwent magnetic resonance imaging (MRI) twice at a 1-year interval. The annual rate of hippocampal atrophy of each subject was determined by using an MRI-based volumetric technique. Background characteristics, age, sex, disease duration, education, MRI interval, apolipoprotein E (APOE) genotype, and baseline Alzheimer’s Disease Assessment Scale score were comparable between the treated and control groups. RESULTS: The mean annual rate of hippocampal volume loss among the treated patients (mean=3.82%, SD=2.84%) was significantly smaller than that among the control patients (mean=5.04%, SD=2.54%). Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer’s Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant. CONCLUSIONS: Donepezil treatment slows the progression of hippocampal atrophy, suggesting a neuroprotective effect of donepezil in Alzheimer’s disease.

This article has been cited by other articles:

				N. Schuff, N. Woerner, L. Boreta, T. Kornfield, L. M. Shaw, J. Q. Trojanowski, P. M. Thompson, C. R. Jack Jr, M. W. Weiner, and the Alzheimer's; Disease Neuroimaging Initiative MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers Brain, April 1, 2009; 132(4): 1067 - 1077. [Abstract] [Full Text] [PDF]

				J T O'BRIEN Role of imaging techniques in the diagnosis of dementia Br. J. Radiol., December 1, 2007; 80(Special_Issue_2): S71 - S77. [Abstract] [Full Text] [PDF]

				C. G. Ballard, K. A. Chalmers, C. Todd, I. G. McKeith, J. T. O'Brien, G. Wilcock, S. Love, and E. K. Perry Cholinesterase inhibitors reduce cortical A{beta} in dementia with Lewy bodies Neurology, May 15, 2007; 68(20): 1726 - 1729. [Abstract] [Full Text] [PDF]

				L. C. Walker and R. F. Rosen Alzheimer therapeutics--what after the cholinesterase inhibitors? Age Ageing, July 1, 2006; 35(4): 332 - 335. [Full Text] [PDF]

				V Jelic, M Kivipelto, and B Winblad Clinical trials in mild cognitive impairment: lessons for the future J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 429 - 438. [Abstract] [Full Text] [PDF]

				Emerging Perspectives: New Ways to Predict and Treat Alzheimer Disease Journal Watch Psychiatry, May 18, 2005; 2005(518): 4 - 4. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us